<?xml version="1.0" encoding="UTF-8"?>
<p>Multiple clinical observations suggested that patients with cytomegalovirus (CMV) disease who were treated with rapamycin demonstrated better outcomes and were better able to control CMV viremia than patients treated with standard calcineurin inhibitor-based immunosuppression following transplantation [
 <xref rid="r74" ref-type="bibr">74</xref>, 
 <xref rid="r80" ref-type="bibr">80</xref>]. In 2009, two seminal studies of sirolimus demonstrated the immunostimulatory effects of rapamycin on the CD8+ memory T cell response following pathogen infection [
 <xref rid="r74" ref-type="bibr">74</xref>, 
 <xref rid="r80" ref-type="bibr">80</xref>]. Later studies also showed that monkeys treated with sirolimus exhibited increased recall responses and enhanced differentiation of memory T cells following vaccination with Modified Vaccinia Ankara [
 <xref rid="r81" ref-type="bibr">81</xref>].
</p>
